<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03430466</url>
  </required_header>
  <id_info>
    <org_study_id>kbcrnb001</org_study_id>
    <nct_id>NCT03430466</nct_id>
  </id_info>
  <brief_title>Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study to Assess Efficacy, Safety &amp; Immunological Biomarker of Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Breast Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto Breast Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety and efficacy of anti PD-L1 antibody + anti&#xD;
      CTLA-4 antibody in combination with hormone therapy in patients with hormone receptor&#xD;
      positive HER2-negative recurrent or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruiting was not possible&#xD;
  </why_stopped>
  <start_date type="Actual">June 22, 2017</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate based on RECIST1.1</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalmab&amp;Tremelimumab&amp;Fulvestrant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalmab&amp;Tremelimumab&amp;Fulvestrant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalmab&amp;Tremelimumab&amp;Fulvestrant</intervention_name>
    <description>Durvalumab and Tremelimumab once in 4 weeks Durvalumab for 13 months Tremelimumab for initial 4 months Fulvestrant : At baseline, then week 2, week 4 and after that every 4 weeks</description>
    <arm_group_label>Durvalmab&amp;Tremelimumab&amp;Fulvestrant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged &gt;= 20 years at informed consent.&#xD;
&#xD;
          2. Patients who have provided written informed consent themselves.&#xD;
&#xD;
          3. Patients who have metastatic and/or advanced lesion&#xD;
&#xD;
          4. Documentation of ER-positive and/or PR-positive tumor (&gt;=1% positive stained cells).&#xD;
&#xD;
          5. Patients with cancer confirmed to be HER2-negative.&#xD;
&#xD;
          6. Patients with confirmed menopause&#xD;
&#xD;
          7. Patients who have plans of 2nd hormone therapy.&#xD;
&#xD;
          8. Patients with a measurable lesion based on RECIST 1.1&#xD;
&#xD;
          9. Patients with ECOG PS of 0 to 1.&#xD;
&#xD;
         10. Patients without any severe disorder in the major organs.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active or prior documented autoimmune disease within the past 2 years.&#xD;
&#xD;
          2. Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             dose of durvalumab or tremelimumab&#xD;
&#xD;
          3. Patients with central nervous system metastasis&#xD;
&#xD;
          4. Patients with life-threatening disease.&#xD;
&#xD;
          5. Patients with a history of treatment with anti-PD-1, anti-PD-L1, anti-PD-L2 or&#xD;
             anti-CTLA-4 antibody drug.&#xD;
&#xD;
          6. Patients who have received live vaccination within 30 days before start of the&#xD;
             investigational products.&#xD;
&#xD;
          7. Patients with a past medical history of pneumonia requiring steroid treatment or with&#xD;
             a past medical history of interstitial pneumonia.&#xD;
&#xD;
          8. Patients considered ineligible for participation in this study by their attending&#xD;
             physicians.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>February 6, 2018</study_first_submitted>
  <study_first_submitted_qc>February 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

